No Data
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $16
Relay Therapeutics: Promising Clinical Trials and Strategic Positioning Justify Buy Rating
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $12
BofA Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $19
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $12 to $23
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
